Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07444710CT.gov Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07029737CT.gov A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain | — | Recruiting | — | — | — |
NCT06846489CT.gov Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06564038CT.gov A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | — | Recruiting | — | — | — |
NCT06054776CT.gov Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT05951959CT.gov A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05004064CT.gov Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT05934097CT.gov FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT05495464CT.gov A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04883437CT.gov Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | — | Recruiting | — | — | — |
Show 55 more trialsShow fewer
NCT04626791CT.gov Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT04855695CT.gov Avo In R/R And Previously Untreated MCL | — | Recruiting | — | — | — |
NCT04765111CT.gov Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05097443CT.gov Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT04662255CT.gov Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | — | Active Not Recruiting | — | — | — |
NCT04783415CT.gov Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04566887CT.gov Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05164770CT.gov Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT04736914CT.gov Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT04484012CT.gov Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT04189757CT.gov Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04402138CT.gov Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03932331CT.gov Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT03842696CT.gov Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | — | Active Not Recruiting | — | — | — |
NCT04115631CT.gov A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03863184CT.gov Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | — | Active Not Recruiting | — | — | — |
NCT03946878CT.gov Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03623373CT.gov Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT02257242CT.gov Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | — | Completed | — | — | — |
NCT02972840CT.gov A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | — | Active Not Recruiting | — | — | — |
NCT02858258CT.gov ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT02735876CT.gov A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT02858804CT.gov EDOCH Alternating With DHAP for New Diagnosed Younger MCL | — | Completed | — | — | — |
NCT02633137CT.gov Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT02455297CT.gov Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) | — | Terminated | — | — | — |
NCT02427620CT.gov Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02362035CT.gov ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | — | Completed | — | — | — |
NCT01865110CT.gov R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | — | Completed | — | — | — |
NCT01897012CT.gov Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | — | Completed | — | — | — |
NCT01789255CT.gov Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT01812005CT.gov Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT01695941CT.gov Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01567709CT.gov Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT01389427CT.gov Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). | — | Completed | — | — | — |
NCT01397825CT.gov MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | — | Completed | — | — | — |
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01184885CT.gov A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | — | Completed | — | — | — |
NCT01116154CT.gov Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT00878254CT.gov Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00807495CT.gov Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00697346CT.gov Study of MLN8237 in Participants With Advanced Hematological Malignancies | — | Completed | — | — | — |
NCT00703664CT.gov Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
NCT00722137CT.gov Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00791011CT.gov Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | — | Completed | — | — | — |
NCT00601718CT.gov Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00499811CT.gov Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | — | Completed | — | — | — |
NCT00458731CT.gov Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | — | Completed | — | — | — |
NCT00275080CT.gov Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | — | Completed | — | — | — |
NCT00253630CT.gov Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00209222CT.gov Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | — | Unknown | — | — | — |
NCT00285389CT.gov Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | — | Completed | — | — | — |
NCT01851551CT.gov Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | — | Completed | — | — | — |
NCT00005780CT.gov Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00581854CT.gov Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00022945CT.gov Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (+)-Vincristine (this asset) | National Cancer Institute (NCI) | Approved | BB · 70 |
| Etoposide | Ruijin Hospital | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Busulfanum | City of Hope Medical Center | P2 | BBB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Cediranib | City of Hope Medical Center | P2 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for (+)-Vincristine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BBB · 78 |
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 78 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (+)-Vincristine in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →